Publicaciones en colaboración con investigadores/as de Massachusetts General Hospital (94)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  3. APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases

    Frontiers in Molecular Neuroscience, Vol. 17

  4. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  5. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  6. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  7. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  8. MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 6, pp. 1506-1515

  9. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602

  10. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

    JHEP Reports, Vol. 6, Núm. 7

  11. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

2023

  1. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  2. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    Nature Communications, Vol. 14, Núm. 1

  5. Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome

    Annals of surgery, Vol. 278, Núm. 5, pp. e1041-e1047

  6. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome

    Hepatology, Vol. 77, Núm. 5, pp. 1527-1539

  7. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

  8. Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors

    STAR Protocols, Vol. 4, Núm. 1

  9. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology